AROENaC1001: A Phase 1/2a Dose-Escalating Study to Evaluate the Safety, Tolerability and Pharmacokinetic Effects of ARO-ENaC in Normal Healthy Volunteers and Safety, Tolerability and Efficacy in Patients with Cystic Fibrosis

  • Phillips, Sandy S. (PI)
  • Brenner, Meinrad (PI)
  • Wallace, Douglas D. (PI)

Project: Research project

Project Details

Description

ARO-ENAC is being developed to treat people with Cystic Fibrosis by blocking the expression of a protein which may lead to improved mucus hydration and clearance and may prevent further lung injury.

StatusFinished
Effective start/end date10/1/01 → 12/1/21

Funding

  • Social Sciences and Humanities Research Council of Canada: US$5,811,707.00

ASJC Scopus Subject Areas

  • Genetics(clinical)
  • Pulmonary and Respiratory Medicine
  • Pharmacology
  • Medicine(all)
  • Organic Chemistry
  • Renewable Energy, Sustainability and the Environment

Access Project